Daxor Corporation

Daxor Corporation

DXR·NASDAQ

$11.09

+3.3%
HealthcareMedical - Instruments & Supplies

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

At a Glance

Live Snapshot
Market Cap$55.86M
EPS1.8400
P/E Ratio6.03
Earnings Date08/20/2026

dxr

Change in Working Capital

Last Annual Value

21.23K

3-Year CAGR

63%

5-Year CAGR

22%

10-Year CAGR

-23%

Daxor Corporation

Daxor Corporation Competitors Analysis of Change in Working Capital

DXR · NASDAQ
CompanyChange in Working Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
21.23K
-26.1%-37.2%N/A 
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
1.47M
80.1%N/A-25.4%
3.29M
4.3%-2.5%N/A
-2.03M
N/AN/AN/A
0.00
N/AN/AN/A
-1.93M
N/AN/AN/A
-3.95M
N/AN/AN/A
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
-440.66K
N/AN/AN/A
-11.68M
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
3.64M
10.2%-46.1%22.6%
1.41M
-35.1%N/AN/A
Daxor Corporation

Daxor Corporation Fair Value Envelope

DXR · NASDAQ

Our analysis suggests that DXR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.0866, this represents a potential HIDDEN relative to our calculated worth for Daxor Corporation.

Intrinsic Value
Current Price: $11.0866